Bayerische Motoren Werke ADR (BMWYY)

Spotlight Diagnostics, a startup based in Eindhoven, Netherlands, is developing a test kit that will enable personnel to rapidly test for infectious diseases without requiring lab facilities . The kit targets infectious diseases like malaria, Chlamydia, gonorrhea and others that take a huge toll on human life.

Las Vegas, Nevada - July 10, 2025 - The retrofittable SmartTOP roof top module for the Ferrari Portofino M is now available. The latest development from Mods4cars makes everyday convertible use easier thanks to intelligent additional functions.“In addition to the Ferrari 360, F430 Spider, 458/488 Spider, California, F8, 296 GTS, and Portofino, we can now offer a convenient solution for the Ferrari Portofino M as well,” says PR spokesperson Sven Tornow.

Libertyville, IL () July 10, 2025 -- Auto Lab Libertyville expands into full-spectrum BMW maintenance, expertly addressing car owners’ issues and concerns.

A new study that has been published in JAMA Network has found that military veterans that sustained traumatic brain injuries (TBIs) had an elevated risk of developing cancerous brain tumors. Doctor Ian Stewart, who led this breakthrough study, explains that his team found that veterans that sustained moderate or severe TBIs had their likelihood of developing brain cancer increase by 90%.

Luxury San Francisco-based limo company Limo SF VIP (888 888-0195) announces private chauffeured transportation services to and from major and smaller airports throughout the Bay Area.

Brighton and Hove, Brighton () July 8, 2025 -- Bike Buyer UK makes it easier than ever to get a fast, fair, and free valuation for motorcycles with no pressure to sell.

University of Sydney researchers have, for the first time ever, targeted a malfunctioning protein in mice having symptoms akin to Parkinson’s symptoms and successfully improved motor function in the mice. This breakthrough finding could open the door to finding a similar way to treat Parkinson’s disease in humans.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, Inc., a multi-site clinical care delivery organization, recently signed a binding letter of intent to acquire a 49% stake in Cohen and Associates, LLC, a respected neuropsychiatry clinic based in western Florida ( https://ibn.fm/geIxF ).

GMV Car Parts (+447367808606) has increased its workforce to strengthen service delivery for tyre pressure monitoring systems (TPMS) and essential automotive components across the UK.

Rob Bonta, the Attorney General of California, revealed on Tuesday that 20 states have filed a lawsuit challenging the federal government’s release of private Medicaid data to deportation personnel in June. The shared data affects millions of people enrolled in Medicaid.

Mainz, Germany, July 5, 2025 -- As the global shift toward electric mobility accelerates, BTR New Material Group showcased at the 15th Advanced Automotive Battery Conference (AABC) Europe to present its cutting-edge materials roadmap for next-generation batteries.

The opioid crisis remains one of the most pressing public health challenges of our time. While synthetic opioids like fentanyl play a crucial role in managing severe pain, their high abuse potential has led to a growing demand for smarter, safer delivery systems. As policymakers, healthcare providers, and regulators seek solutions that balance medical necessity with public safety, innovative technologies are emerging that could reshape how these powerful drugs are administered.

While studying why non-human primates aren’t as likely to suffer from certain cancers when compared to humans, UC Davis scientists discovered a genetic mutation that could explain this anomaly. Their findings were published in the Nature Communications journal. This discovery could open the door to the development of more powerful treatments for cancer.

In a recent webinar hosted by Allele Capital, Soligenix (NASDAQ: SNGX) executives Dr. Christopher Schaber and Dr. Christopher Pullion shared detailed updates on the company’s HyBryte(TM) (synthetic hypericin) clinical development ( https://ibn.fm/dz7eO ). The event offered an in-depth look at Soligenix’s ongoing confirmatory phase 3 trial for cutaneous T-cell lymphoma (“CTCL”), a rare non-Hodgkin’s lymphoma, and discussed promising data emerging from an investigator-initiated study conducted at the University of Pennsylvania. Soligenix, a late-stage biopharmaceutical company, is dedicated to developing and commercializing treatments for rare diseases and unmet medical needs, and HyBryte(TM) represents the company’s lead asset aimed at transforming the treatment landscape for CTCL.

Oragenics (NYSE American: OGEN) a developer of intranasal pharmaceuticals for neurological disorders, has entered into a placement agency agreement for the sale of up to 800,000 shares of Series H Convertible Preferred Stock and accompanying Warrants, priced at $25.00 per unit. Each Warrant allows purchase of an additional Preferred share at $25.00, with Preferred shares convertible into common stock at $2.50. Gross proceeds could total $20 million, which will support ONP-2 concussion trials, R&D, repayment of a $3 million bridge note, and general corporate needs. Dawson James Securities, Inc. is acting as sole placement agent, with closing expected on or about July 2, 2025.

Existing scientific information shows that pesticides are toxic to the microorganisms in the gut, and a new preclinical study has mapped the specific impacts that compounds in pesticides have on microbes in the human digestive system. One surprising finding emerged regarding how these pesticide compounds affect the inflammatory system in the body.

Nutriband (NASDAQ: NTRB) has been added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 Russell indexes reconstitution. CEO Gareth Sheridan called the inclusion a reflection of market recognition and momentum behind the company’s AVERSA pipeline, particularly AVERSA Fentanyl, which has potential peak annual U.S. sales between $80 million and $200 million. Russell indexes, maintained by FTSE Russell, benchmark approximately $10.6 trillion in assets and are widely used by investment managers and institutions.

NextPlat (NASDAQ: NXPL, NXPLW) released a shareholder letter from Interim CEO expressing confidence in the company’s future following the recent passing of CEO and Chairman Charles M. Fernandez. The letter highlights internal reviews, meetings with subsidiary leaders, and plans for increased focus, coordination, and strategic investment to build on the company’s existing foundation and drive long-term value creation.

Panda Hub announces expansion across 15 U.S. states and 2 Canadian provinces, offering mobile car detailing services with certified professionals and sustainable practices.

University of Plymouth researchers in the UK have identified the proteins that underlie the growth and development of common brain tumors. Their findings could, in the long run, trigger the development of new treatments which are less invasive.

According to recent industry data, interest in pre-owned vehicles has surged due to ongoing supply chain constraints affecting new car production and rising inflation rates. Select Automotive’s latest move positions the dealership as a key player in addressing this gap, with dozens of new arrivals added to its lot this month alone.

Adageis offers providers tools that simplify operations and improve financial performance as healthcare shifts further toward value-based care. “One of the core advantages Adageis offers is the clarity it brings to complex healthcare systems. Its platform is designed to be simple for clinics to navigate, allowing physicians and administrators to see which of their services yield the highest value. This supports decision-making around treatment priorities while maintaining quality standards,” reads a recent article. “Instead of relying on outside consultants or navigating spreadsheets, practices can use the software to pinpoint which services align best with revenue and care standards. The platform aims to make this information more accessible to staff without a technical background.”

Annovis Bio (NYSE: ANVS), a late-stage clinical company focused on therapies for neurodegenerative diseases, announced its leadership will attend the Alzheimer’s Association International Conference (AAIC) from July 27–31, 2025, in Toronto. The company will present four scientific posters detailing progress on its Alzheimer’s clinical program and pharmacokinetic data for its lead candidate, buntanetap. Topics include the design of a Phase III trial, efficacy and safety data, and comparative pharmacokinetics of different drug formulations in both animals and humans.

Today, more ordinary people are taking an interest in tracking their mitochondrial health in order to take concrete steps to improve their overall wellness and boost longevity. Previously, such interest was a mainstay among elite athletes, scientists and biohacking enthusiasts. Why are more people choosing to have their mitochondrial health tested?

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharma company focused on inflammation and immunology, announced that Dr. Roberta Lotti of Pincell Srl has won the “Oscar of Italian Dermatology” from SIDeMaST for her research on PC111, a first-in-class anti-Fas Ligand monoclonal antibody. The study, published under the title “Blocking soluble Fas Ligand ameliorates pemphigus” , confirms PC111’s ability to block blister formation by preventing keratinocyte apoptosis in pemphigus vulgaris. Scinai holds an option to acquire Pincell and is advancing PC111 as a lead asset, emphasizing its potential as a non-immunosuppressive, disease-modifying treatment for severe autoimmune skin conditions.